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The family of G-protein-coupled receptors (GPCRs) is one of the most important drug
targets. Mechanisms underlying GPCR activation and signaling are therefore of great
pharmacologic interest. It was long thought that GPCRs exist and function as monomers.
This feature was considered to distinguish GPCRs from other membrane receptors
such as receptor tyrosine kinases or cytokine receptors, which signal from dimeric
receptor complexes. But during the last two decades it was increasingly recognized that
GPCRs can undergo aggregation to form dimers and higher order oligomers, resulting
in homomeric and/or heteromeric protein complexes with different stoichiometries.
Moreover, this protein complex formation could modify GPCR signaling and function.
We contributed to this paradigm shift in GPCR pharmacology by the discovery of the
first pathologic GPCR aggregation, which is the protein complex formation between
the angiotensin II AT1 receptor and the bradykinin B2 receptor. Increased AT1-B2
heteromerization accounts for the angiotensin II hypersensitivity of pregnant women
with preeclampsia hypertension. Since the discovery of AT1-B2, other pathologic GPCR
aggregates were found, which contribute to atherosclerosis, neurodegeneration and
Alzheimer’s disease. As a result of our findings, pathologic GPCR aggregation appears
as an independent and disease-specific process, which is increasingly considered as a
novel target for pharmacologic intervention.
Keywords: G-protein-coupled receptor, oligomerization, preeclampsia, atherosclerosis, Alzheimer’s disease,
neurodegeneration, biased agonist, beta-arrestin
INTRODUCTION
G-protein-coupled receptors (GPCRs) constitute one of the largest gene families in the human
genome, and provide the target for about 20–30% of all drugs currently on the market. Since the
discovery of rhodopsin and the beta-adrenergic receptor as first GPCRs (1, 2), currently more
than 800 different genes are classified as members of the GPCR family. The pharmacologic and
biologic importance of this huge receptor family led to enormous efforts world-wide to delineate
activation and signaling mechanisms of GPCRs. A common theme of GPCRs is their seven
membrane-spanning domain structure (3), which makes this type of protein a versatile platform
for sensing of a panoply of different signals and stimuli including light, stress, hormones, peptides,
proteins, ions, volatile odorants, tastants, and mechanical forces.
The seven membrane-spanning domain structure distinguishes GPCRs from other membrane
receptors, which are, e.g., single-pass membrane proteins such as tyrosine kinase receptors or
cytokine receptors (4). Consequently, major differences between GPCRs and these non-GPCR
membrane receptors were found. The major distinguishing feature is that GPCRs signal through
activation of heterotrimeric G-proteins, which gives the name to this class of receptors (5, 6).
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Mechanistic studies of GPCR proteins focused on the
identification of features, which account for GPCR-mediated
G-protein activation. A major understanding came from
experiments with receptor-derived peptides, which encompass
segments of the second, third or fourth cytoplasmic domain of
a GPCR and are capable to activate G-proteins independently
of the presence of the entire transmembrane-spanning GPCR
(7, 8). Other studies with purified receptor preparations
found that interaction of a single GPCR with a single G-
protein was a sufficient cause for G-protein activation (9, 10).
Consequently, based on a 1:1 stoichiometry between a GPCR
and a heterotrimeric G-protein, it was concluded that GPCRs
function as monomers, and this feature distinguishes GPCRs
from other membrane receptors such as tyrosine-kinase
receptors or other monotopic transmembrane receptors,
which require dimerization for receptor activation and
signaling (4).
In contrast to these apparently conclusive data, many
researchers, who worked with purified GPCRs, found protein
aggregation of GPCRs in vitro, by gel filtration and on
SDS-PAGE, and cooperative effects in various experimental
settings. All these data could be interpreted as evidence
for a dimeric/oligomeric assembly of GPCRs under certain
experimental conditions. The first thematic study on GPCR
dimerization was published in 1996 by the group of Michel
Bouvier, who reported the functional characterization of GPCR
dimers formed of beta-2-adrenergic receptors expressed in
Sf9 cells (11). This was the beginning of a new era, and
many other researchers started to report their “forbidden”
findings of GPCR dimerization with transfected and endogenous
receptors. But the question of relevance of GPCR dimerization
still remained because most studies were performed with
overexpressed receptors. There was the identification of the
GABA(B) receptor (GABA-B; GABBR) heterodimer composed
of GABBR1 and GABBR2, which as a class C GPCR relies
on receptor dimerization for protein folding and function
(12, 13). According to the A-F classification scheme of
GPCRs, class C receptors contain a huge N-terminal clam-
shaped domain with almost 600 amino acid residues (14,
15). This extracellular region of GABA-B receptors forms a
dimer even in the absence of the transmembrane domain-
containing protein core (15). Therefore, it was concluded
that GABBR is a unique example of a GPCR that requires
heterodimerization for functionality whereas for most other
GPCRs, dimerization is a redundant process and has no obvious
in vivo relevance.
Beginning from 1999, we initiated an independent research
project on GPCR homo- and heterodimerization, which was
based on our previous unpublished data in the early nineties.
And we discovered the first pathologically relevant GPCR
hetero(di)mer, which is the protein complex formed between the
vasopressor angiotensin II AT1 receptor and the vasodepressor
bradykinin B2 receptor (16, 17). We found that increased protein
complex formation between AT1 and B2 on circulating blood
cells and vessels of patients with preeclampsia hypertension
contributes to the angiotensin II hypersensitivity of this severe
pregnancy-specific complication (17, 18). Our findings were
intensely disputed (19), and final acceptance of our findings
only came after more than a decade of scientific discussions
(20). Meanwhile, our findings contributed to a paradigm shift in
GPCR pharmacology, which is now on the verge to lead to new
pharmacologic treatment approaches (21). The following article
briefly overviews the timeline of the discovery of pathologic
GPCR aggregation (Figure 1).
FIRST EVIDENCE OF AN INTERACTION
BETWEEN THE BRADYKININ B2
RECEPTOR AND THE ANGIOTENSIN II AT1
RECEPTOR IN THE EARLY 1990s
(1990-1994)
Our discovery of a functional AT1-B2 receptor protein complex
began in the early 1990s at the Institute of Pathobiochemistry
of the University of Mainz (Germany), where our key findings
were made during a project on the protein purification of the
bradykinin B2 receptor from native human skin fibroblasts
applying ligand and antibody affinity chromatography. This
work was performed in frame of a common project between
U. Quitterer and S. AbdAlla, who led the protein purification
group. He found by amino-terminal protein sequencing that
enrichment of the bradykinin B2 receptor protein, yielded co-
enrichment of the angiotensin II AT1 receptor. At the same
time, these data were complemented by U. Quitterer’s functional
studies, which showed that angiotensin II could induce a
conformational change at the bradykinin B2 receptor with a
shift of the B2 receptor from a high affinity to a low affinity
binding state for the agonist bradykinin. This affinity shift could
reflect a conformational change imposed by the activated AT1
receptor on the associated B2 receptor with subsequent G-protein
activation and uncoupling of the B2 receptor, as a process
which is known of other GPCRs to decrease agonist affinity (22,
23). “We discovered receptor heterodimers,” was the immediate
interpretation of S. AbdAlla, who came from the Heinrich-
Pette-Institute, Hamburg (Germany), where he had worked on
dimerization of interleukin-2 and interleukin-2 receptors. But
when we presented our data and the idea of AT1-B2 receptor
dimerization to the Head of the Institute, he opposed this concept
because in the GPCR field, protein dimerization does not exist.
This was the end of our project on AT1-B2 receptor dimerization
in Mainz (Figure 1).
DISCOVERY OF AT1-B2 AS THE FIRST
PATHOLOGIC GPCR HETEROMER
(1999-2001)
After completion of the doctorate at the University of Mainz
in 1994, and a postdoctorate at Roche Bioscience (Palo Alto,
CA, USA) in 1995, U. Quitterer moved to the Institute of
Pharmacology at the University of Wuerzburg (Germany) to
continue research on GPCRs in 1996. Only 1 year later, in 1997,
she re-established contacts with S. AbdAlla, who at that time
became professor of biochemistry at the newly founded Genetic
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FIGURE 1 | Timeline of the discovery of pathologic GPCR aggregation.
Engineering and Biotechnology Research Institute (GEBRI) in
Alexandria, Egypt. We continued our work on AT1-B2 receptor
heterodimerization, and during our studies, we discovered and
characterized functional bradykinin B2 receptor homodimers in
1999 (24). The project on GPCR dimerization was conducted
together with Dr. Heinz Lother, who invited S. AbdAlla as a
visiting scientist into his labs at the Heinrich-Pette-Institute,
Hamburg (Germany). After we had opened the path for
the concept of receptor dimerization in the kinin field in
1999, the study on AT1-B2 receptor heteromerization was
finished in a short time, and in the year 2000, we published
the discovery of AT1-B2 receptor heteromerization in Nature
[Figure 1; (16)].
The identified heteromeric protein complex between AT1 and
B2 receptors was functional, and led to enhanced angiotensin
II AT1-mediated G-protein activation and signaling. The
B2-mediated sensitization of the AT1 receptor-mediated
response was independent of B2 receptor stimulation
with the agonist bradykinin because a B2 receptor mutant
with defective bradykinin binding still enhanced the AT1-
stimulated G-protein activation and signaling. In contrast, a
B2 receptor mutant with defective G-protein activation due
to a mutation in the DRY motif in the 2nd intracellular loop
of the B2 receptor was incapable to enhance AT1-stimulated
signaling (16). These data are compatible with the notion
that activation of the AT1 receptor by angiotensin II imposes
a conformational change onto the associated unstimulated
B2 receptor, which in turn adopts an active conformation
capable to promote GDP-GTP exchange of the B2-coupled
G-protein with subsequently enhanced signaling (Figure 2).
The heteromeric AT1-B2 protein complex thus could constitute
a platform, which enables enhanced G-protein activation
(Figure 2).
The study of the AT1-B2 heteromer was complemented by
our discovery of the AT1-AT2 receptor complex, which is a
prototype of an inhibitory GPCR interaction [Figure 1; (25)]. In
contrast to the B2 receptor, which enhances the angiotensin II
AT1-stimulated G-protein activation (16, 17), the angiotensin II
AT2 receptor inhibits the activation of the AT1 receptor by direct
protein interaction (25). Thus, GPCR dimerization is capable to
modulate the activation state of the dimerizing partner by direct
interaction. As a consequence, dimerization could enhance or
dampen the guanine nucleotide exchange factor-like function of
a GPCR toward the heterotrimeric G-protein.
A major point in the field of GPCR dimerization and
oligomerization always was the question about physiologic
and pathophysiologic relevance. Most experiments on GPCR
dimerization were made with transfected receptors and/or with
cultured cells. Therefore, our focus immediately shifted to the
question: Does AT1-B2 heteromerization occur in vivo? We
knew that angiotensin II hypersensitivity was a major feature of
preeclampsia hypertension (26, 27), which is the most frequent
pregnancy-related complication with no cure. To study the role
of AT1-B2 heteromerization in preeclampsia, S. AbdAlla initiated
a collaboration with the Medical Research Center (MRC) at
Ain Shams University, Cairo. The head of MRC, Prof. Adel el
Missiery, strongly supported the project because preeclampsia
has a high frequency among women in Egypt. Our study found
that AT1-B2 contributes to the angiotensin II hypersensitivity
of women with preeclampsia (17). This publication of “Receptor
double-trouble in preeclampsia” (17, 18) marks the discovery of
the first pathologic GPCR oligomer (Figure 1).
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FIGURE 2 | Scheme of the AT1-B2 heteromer, which forms a platform for enhanced G-protein activation (right) compared to a monomeric AT1 receptor (left).
In this study, the AT1-B2 receptor heteromer was identified
in vivo, after covalent stabilization with a cleavable cross-
linker followed by affinity enrichment with AT1 receptor-
specific antibodies and subsequent immunoblot detection
of the co-enriched B2 receptor. This approach detected a
significantly higher content of AT1-B2 heteromeric complexes
on platelets and omental vessels from preeclampsia patients
compared to biopsy specimens from uncomplicated pregnancies
(17). Reciprocal experiments with enrichment of B2 and
detection of co-enriched AT1 receptor gave similar results, and
confirmed the disease-related AT1-B2 receptor aggregation in
preeclampsia (17).
Our study also shows that augmented AT1-B2 receptor
protein complex formation is disease-relevant and contributes
to the well-established angiotensin II hypersensitivity in
preeclampsia with enhanced angiotensin II-stimulated calcium
signaling of platelets isolated from preeclamptic women
(17, 26, 27). Sensitization of the angiotensin II-stimulated
response is mediated by the AT1-B2 receptor heteromer not
only in transfected cells but also in patients with preeclampsia
(17). This conclusion was proved by domain-specific antibodies,
which shielded the connecting loop between membrane domains
III-IV of the bradykinin B2 receptor. With these antibodies, we
found that the bradykinin B2 receptor protein is involved in
angiotensin II-stimulated AT1-B2-mediated G-protein activation
on omental vessels isolated from preeclamptic patients. Notably,
the angiotensin II-stimulated response was largely blocked by
these domain-specific antibodies to the connecting loop between
membrane domains III-IV of the bradykinin B2 receptor
whereas control antibodies had no effect (17). Together these
findings complement our previous data on AT1-B2, which show
that mutation of the DRY motif in the same connecting loop
between membrane domains III-IV of the B2 receptor abolishes
the B2-mediated sensitization of the angiotensin II-stimulated
response triggered by the AT1-B2 heteromer (16).
In subsequent years, the pathophysiologic importance of
aberrant AT1-B2 aggregation was supported by additional
studies. Notably, AT1-B2 receptor heteromerization was found
to enhance endothelin-1 release [Figure 1; (28)], which now
is known as a major factor contributing to symptoms of
preeclampsia (29).
DISCOVERY OF COVALENTLY STABILIZED
AT1 RECEPTOR DIMERS WITH
PATHOLOGIC RELEVANCE FOR
CARDIOVASCULAR DISEASE AND
ATHEROSCLEROSIS IN 2004
After elucidation of the pathologic relevance of AT1-B2 receptor
heteromerization, we continued our search for aberrant GPCR
dimerization as contributor to pathomechanisms of disease.
In view of our previous studies, we focused on disease states
with angiotensin AT1 receptor hypersensitivity and found an
increased content of covalently stabilized AT1 receptor dimers
on monocytes isolated from the peripheral blood of patients
with hypertension (30). This finding of stable AT1 dimerization
on monocytes of hypertensive patients in the year 2004 marks
the discovery of the first covalently stabilized GPCR dimer in
human pathology [Figure 1; (30)]. The covalent stabilization of
AT1 receptor dimers was unprecedented and mediated by an
exaggerated intracellular transglutaminase factor XIIIA activity
in patients with increased cardiovascular risk factors (30).
The crosslinking activity of the intracellular factor XIIIA
does not rely on thrombin, which activates circulating factor
XIIIA in plasma by proteolytic cleavage as part of the
blood clotting cascade. Instead, the transglutaminase activity
of intracellular factor XIIIA could be activated by an altered
cellular ion homeostasis, increased cytosolic calcium and/or
oxidative stress (30). All these causes of intracellular factor XIIIA
transglutaminase activation are promoted by cardiovascular
risk factors such as hypertension, hypercholesterolemia, and
atherosclerosis. In concert with induction of factor XIIIA gene
expression and protein in monocytes by cardiovascular risk
factors (30), the consecutively exaggerated intracellular factor
XIIIA activity accounts for covalent stabilization of AT1 receptor
dimers, which are triggered by increased circulating angiotensin
II levels in patients “at the onset of atherosclerosis” (30–32).
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Our functional studies show that covalent stabilization of
AT1 receptor dimers accounts for angiotensin II hypersensitivity
in vivo and contributes to the atherogenic function of the
AT1 receptor on monocytes of patients with cardiovascular
disease and hypertension (30). Apart from disease relevance,
our studies also confirm our previously established concept of
modulation of G-protein activation by receptor dimerization:
covalent stabilization of AT1 receptor homodimers creates a
receptor platform, which enables efficient G-protein activation
compared to AT1 receptor monomers and/or dissociable AT1
receptor complexes (30–32).
MOVE TO ETH ZURICH AND DISCOVERY
OF PATHOLOGIC GPCR AGGREGATION IN
ALZHEIMER’S DISEASE (2006–2009)
Our work on the discovery of pathologic GPCR aggregation
was highly recognized by the international scientific community.
The initial publication in Nature in the year 2000 (16) was
ranked top 1% in the scientific field according to ISI web of
science. Meanwhile this publication is cited more than 500
times. The discovery of AT1-B2 heteromerization as the first
pathologic GPCR aggregation also became international textbook
knowledge and was included in the “Blue Bible,” which is
the nickname of the 12th edition of Goodman Gilman‘s The
Pharmacological Basis of Therapeutics (33). Another highlight
was the Wenner Grenn Symposium on GPCR dimerization in
Stockholm in 2004. Kjell Fuxe from Karolinska Institute invited
major players in the field of GPCR dimerization to Stockholm.
During the meeting, U. Quitterer had the chance to dispute the
existence and pathologic relevance of GPCR aggregation on stage
with Robert Lefkowitz, who later received the Nobel Prize in
Chemistry, in the year 2012, for studies on G-protein-coupled
receptors. The discussion was moderated by Michel Bouvier,
who supported U. Quitterer‘s statements and conclusions. With a
high international reputation, the President of ETH Zurich, Prof.
Olaf Kübler, offered U. Quitterer at the age of 39, the Chair of
Molecular Pharmacology at ETH Zurich. She accepted the offer
in summer 2005, and was nominated full professor and Chair of
Molecular Pharmacology by the ETH Counsil at the end of 2005.
We moved into newly refurbished ETH labs at the beginning of
2006.
At ETH Zurich, we continued our work on pathologic GPCR
aggregation. Stimulated by ongoing discussions on existence
and mechanisms of GPCR aggregation, our focus shifted to
Alzheimer’s disease (AD). We reasoned that GPCR aggregation
should readily be detectable in a typical protein aggregation
disease. We searched for covalently stabilized GPCR aggregates
as a consequence or cause of Alzheimer senile plaques, because in
a previous study, we found covalently stabilized GPCR aggregates
formed of the angiotensin II AT1 receptor in atherosclerosis (30),
which is also a “plaque-forming” disease. With this concept in
mind, we discovered SDS-stable aggregates of the angiotensin
II AT2 receptor as a characteristic feature of AD patient biopsy
specimens isolated from prefrontal cortex (34, 35). Covalent
aggregation of AT2 receptor oligomers is disease-specific for
AD because related GPCRs such as the AT1 receptor are not
aggregated in AD brains (34). The identification of covalently
cross-linked AT2 receptor oligomers in brains of AD patients
extends the pathologic relevance of aberrant GPCR aggregation
to neurodegenerative diseases (Figure 1).
Why does the AT2 receptor form high molecular weight
aggregates in brains of AD patients? We investigated the
underlying mechanism and found that AT2 receptor aggregation
in AD is a disease-specific process with two consecutive cross-
linking steps, i.e., mediated by (i) reactive oxygen species (ROS),
and (ii) transglutaminase. Initially, we aimed to deduce the
AD-specific mechanism of AT2 aggregation in the transgenic
Tg2576 AD model with neuron-specific expression of APPSwe,
which is a mutant of the amyloid precursor protein (APP)
isolated from a Swedish family with familial AD (36). Tg2576
AD mice reproduce major AD features such as symptoms of
neuronal degeneration, cognitive impairment and beta-amyloid
(Abeta) plaques in the hippocampus starting at an age of 12
months. However, Tg2576 mice did not develop pathologic
AT2 oligomers but only showed the initial ROS-dependent
AT2 crosslinking step, which leads to stable AT2 dimers (34).
In search for the mechanism of pathologic AT2 aggregation in
AD, we realized that aged Tg2576 AD mice are largely devoid
of neuronal loss, which is a major characteristic of AD patients
(34). To enhance the process of neurodegeneration, we subjected
aged Tg2576 AD mice to chronic unpredictable mild stress
(CUMS), which mimics psychosocial stress as an established
risk factor for AD in patients (37). Chronic unpredictable mild
stress augmented the hippocampal transglutaminase activity
of Tg2576 mice, and triggered the final transglutaminase-
mediated crosslinking of oxidized AT2 dimers to AD-related
and pathologic AT2 oligomers. Concomitantly, chronic
unpredictable mild stress increased hippocampal Abeta
accumulation, promoted neurodegeneration-enhancing PHF
tau phosphorylation and induced overt neuronal loss in the
hippocampus of Tg2576 mice.
Cellular accumulation of covalently cross-linked AT2 receptor
oligomers is pathologic and contributes to neurodegeneration
and neuronal loss, which are hallmarks of AD brains.
The pathologic AT2 receptor aggregates promote neuronal
deterioration in AD by sequestration and inhibition of cognition-
enhancing Gq/11-mediated-signaling stimulated, e.g., by the
M1-cholinoceptor (34, 35). In agreement with this notion,
inhibition of AT2 receptor oligomerization retarded symptoms
of neurodegeneration in the experimental AD model (35). Our
ongoing studies aim to translate these experimental findings
into a therapeutic strategy to restore the function of the
neuroprotective AT2 receptor and halt disease progression in AD
models and patients (34, 35).
DIFFICULTIES TO DETECT AT1-B2
RECEPTOR HETEROMERIZATION
Immediately after the discovery of covalent AT2 receptor
aggregation in AD (34, 35), the research on neurodegenerative
GPCR aggregation in Alzheimer’s disease was interrupted by
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FIGURE 3 | A beta-arretin-biased agonist targets the AT1-B2 heteromer and promotes AT1-B2 down-regulation (right). The unbiased AT1 antagonist does not
promote AT1-B2 down-regulation (left).
a publication, which reported “lack of evidence for AT1R/B2R
heterodimerization” (19). When we saw this and similar other
publications (19, 38), we realized that we had to redirect our
research toward the AT1-B2 heteromer.
In search for causes, which could account for the failure
to detect the AT1-B2 receptor heteromer in transfected cells,
we focused on the role of chaperones because chaperones
are critically influenced by variable cell culture conditions
(39). Whole genome microarray gene expression profiling
identified the chaperone, calreticulin, as an important factor
required for efficient B2 receptor maturation and AT1-B2
heteromerization (39). Loss of essential chaperones during in
vitro cell culture could be a cause for failure to detect AT1-
B2 (39). To overcome limitations of in vitro cell culture,
we established cell expansion conditions, which mimic the
in vivo environment because our studies mainly focus on
GPCR aggregation under pathologic conditions in vivo. The
in vivo cell expansion model applies NOD.Scid mice for
expansion of cultured cells. Microarray gene expression analysis
documented that the expression of essential chaperones is
restored upon in vivo expansion of cultured cells in NOD.Scid
mice (40).
Another critical factor is the intrinsic pathologic nature
of the AT1-B2 heteromer, which could contribute to further
difficulties to detect AT1-B2 in transfected cells. Expression
of functional AT1-B2 heteromers leads to exaggerated calcium
signaling with consecutively reduced cellular growth rates,
premature senescence, and ultimately calcium-induced cell death
(41, 42). Consequently, only slow-growing cells with low AT1-
B2 expression level will survive. Under these conditions, there
is a high risk that the cell culture dish is rapidly overgrown by
fast dividing, non-transfected cells and/or cells expressing either
AT1 or B2. This scenario is particularly relevant for in vitro
cultured cells due to the loss of essential pro-survival factors,
e.g., components of the pro-survival ERK pathway (43). Control
experiments, which control for co-expression of AT1-B2 at the
single cell level are necessary to identify and overcome such
problems.
At present, it is not clear, why several groups failed to
detect AT1-B2 receptor heteromerization in transfected cells.
While we addressed some possible issues, a definite answer
is not possible because experiments in these publications
were performed with batches of cells, and precise biochemical
and/or histological control experiments are lacking, e.g., the
control for co-expression of AT1 and B2 at the single cell
level, co-immunoenrichment studies and immune-fluorescent
microscopy of receptor proteins (19, 38).
Apart from the above-mentioned causes, a high cellular
expression level of the transfected GPCRs, notably the AT1
receptor, could become another factor of failure to detect AT1-
B2 heteromerization. The documented reporting of constitutive
AT1 receptor homomerization could be indicative of high AT1
receptor expression at the single cell level (19). High AT1
receptor expression at the single cell level could be attributed,
e.g., to the SV40 large T-antigen-driven DNA replication at
high copy number in COS cells (19). A high cellular GPCR
expression level could be a critical factor because it could favor
the formation of receptor homomers over receptor heteromers
(44), i.e., the homomeric interaction between AT1-AT1 could
become dominant and prevent the heteromeric interaction of
AT1 with B2. As mentioned above, essential control experiments
were not performed, e.g., the visualization of AT1 and B2 receptor
proteins by immunoblot to detect protein aggregation and/or
immaturely folded proteins (19, 38).
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Concomitantly with the identification of critical parameters
required for AT1-B2 heteromer formation in cells, we established
a versatile method for detection of the AT1-B2 receptor
heteromer by confocal FRET imaging, which is capable to detect
protein-protein interactions in close proximity at a distance of
<10 nm (45). We added a signal peptide to the AT1 receptor-
cerulean fusion protein, which otherwise barely reached the
cell surface under standard cell culture conditions. With this
approach, we demonstrated a high FRET efficiency of 24.7%
for the interaction between AT1-Cerulean and B2-eYFP (45).
Thus, we had proven that the AT1-B2 receptor heteromer exists
in cultured cells, and can readily be detected by a standard
FRET-based method, which is usually applied for detection
of GPCR dimerization in cells (Figure 1). In addition, we
documented functionality of AT1-B2 receptor heteromerization,
which accounts for receptor co-internalization upon stimulation
with angiotensin II (45).
Taken together, the question, why several groups were unable
to detect AT1-B2 receptor heteromerization in cells, cannot
be answered because specific control experiments were not
performed (19, 38). In contrast, different groups in different
laboratories worldwide demonstrated that AT1-B2 receptor
heteromerization can be detected by different biochemical and
biophysical methods (16, 17, 20, 45).
INDEPENDENT CONFIRMATION OF
AT1-B2 HETEROMERIZATION IN THE
YEAR 2013, AFTER MORE THAN A
DECADE OF SCIENTIFIC DISCUSSIONS
While our own work established the methodology for detection
of functional AT1-B2 heteromerization, final acceptance of AT1-
B2 by the scientific community occurred in 2013, after more
than a decade of scientific discussions (Figure 1). In 2013,
the group of Louis Luttrell, a former member of the Nobel
Prize-winning Lefkowitz lab, reproduced our findings of AT1-
B2 receptor heteromerization (20). With this publication, years
of ongoing scientific discussions were finally resolved. The
publication not only confirmed our initial findings but also
opened the path to a new pharmacologic targeting approach of
the AT1-B2 heteromer by the beta-arrestin-biased AT1 agonist,
SII (Sar1,Ile4,Ile8-AngII) (20).
According to the concept of beta-arrestin-biased agonism,
stimulation of the AT1 receptor by a beta-arrestin-biased
agonist inhibits G-protein-stimulated signaling but promotes the
recruitment of beta-arrestin to the activated AT1-B2 receptor
complex. As a consequence of beta-arrestin recruitment, the
AT1-B2 receptor complex undergoes co-internalization and
subsequent down-regulation (Figure 3).
In contrast, a classic, unbiased AT1 receptor antagonist such
as losartan, blocks both, AT1-stimulated signaling, and beta-
arrestin recruitment to the receptor. Consequently, the AT1-B2
receptor complex is not down-regulated (Figure 3). All currently
approved AT1 antagonists are unbiased and contraindicated
in preeclampsia because they cross the placental barrier and
promote fetal malformations in pregnancy (46). Experimental
beta-arrestin-biased agonists such as SII or TRV027 are peptides
(47, 48) and not expected to cross the placental barrier. Therefore,
such beta-arrestin-biased AT1 agonists could be envisaged as
a future therapy for preeclampsia. Notably, beta-arrestin-biased
AT1 agonists target the AT1-B2 receptor heteromer and promote
AT1-B2 heteromer co-internalization and subsequent down-
regulation (20, 49, 50).
OUTLOOK
Our ongoing studies at ETH Zurich currently address
the feasibility to target the AT1-B2 heteromer and other
pathologic GPCR aggregates by beta-arrestin-mediated down-
regulation. To study such an approach, we generated transgenic
models with increased AT1-B2 heteromerization. With these
transgenic models, the in vivo relevance of AT1-B2 receptor
heteromerization was demonstrated (50). Our data show
that increased vascular AT1-B2 levels are a sufficient cause
for preeclampsia symptoms in pregnant mice [Figure 1; (50)].
Moreover, symptoms of preeclampsia in AT1-B2-transgenic mice
can be prevented by beta-arrestin-mediated down-regulation
of AT1-B2 (50). Thus, targeting of the AT1-B2 heteromer by
beta-arrestin-mediated down-regulation is feasible (50). And
the initial identification of pathologic GPCR aggregation more
than a decade ago is currently being translated into a new
pharmacologic treatment approach.
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